Cytotoxic CD4+ T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway.

Nino Porakishvili1,2
Lela Kardava1
Andrew P. Jewell4
Kwee Yong3
Martin J. Glennie5
Arne Akbar2
Peter M. Lydyard2

1 Department of Immunology, Tbilisi State University, Georgia
2 Department of Immunology & Molecular Pathology, Royal Free & University College Medical School, London, UK
3 Department of Haematology, Royal Free & University College Medical School, London, UK
4 School of Life Sciences, Kingston University, UK
5 Tenovus Research Laboratories, Cancer Sciences Division, University of Southampton

This is an electronic version of an article published in Haematologica, 89 (4). pp. 435-443, April 2004. Haematologica is available online at:


The WestminsterResearch online digital archive at the University of Westminster aims to make the research output of the University available to a wider audience. Copyright and Moral Rights remain with the authors and/or copyright owners. Users are permitted to download and/or print one copy for non-commercial private study or research. Further distribution and any use of material from within this archive for profit-making enterprises or for commercial gain is strictly forbidden.

Whilst further distribution of specific materials from within this archive is forbidden, you may freely distribute the URL of WestminsterResearch.
(http://www.wmin.ac.uk/westminsterresearch).

In case of abuse or copyright appearing without permission e-mail wattsn@wmin.ac.uk.
Cytotoxic CD4+ T cells in patients with B cell chronic lymphocytic leukemia kill via a perforin-mediated pathway

Background and Objectives. B-cell chronic lymphocytic leukemia (B-CLL) is a clonal expansion of CD5+B cells that accumulate due to their uncontrolled growth and resistance to apoptosis. We have previously shown that up to 50% of blood CD4+ T cells in B-CLL patients have a cytotoxicity-related CD28−CD57+ phenotype and high content of both granzyme B and perforin (PF). In this study we investigate the cytotoxic potential of these cells against autologous B-CLL cells.

Design and Methods. Blood CD4+ or CD8+ T cells were positively isolated from B-CLL patients and cultured under a range of conditions with autologous purified B-CLL cells and with bispecific [anti-CD3 × anti-CD19] antibodies. Apoptosis of labeled B-CLL cells was assessed using the change of mitochondrial membrane potential with the fluorescent dye DiOC6 and confirmed by annexin V binding.

Results. There was time- and dose-dependent killing of B-CLL cells by both CD8+ and CD4+ T cells and this ranged from 6.6 - 68.0% for CD4+ cells and 6.4 - 57.8% for CD8+ cells. Almost complete inhibition by concanamycin A suggests that CD4+ T cells like CD8+ T cells induced apoptosis through a perforin-mediated pathway, but not via Fas/FasL (as indicated by lack of blocking with brefeldin A), tumor necrosis factor α or TRAIL.

Interpretation and Conclusions. This study shows that blood CD4+PF+ T cells enriched in B-CLL patients, are able to kill autologous B-CLL cells ex vivo, through bispecific antibodies via a perforin mediated mechanism.

Key words: B-CLL, CD4-cytotoxicity, perforin.
a cytotoxicity-related CD28-CD57+ phenotype and high content of both granzyme B and PF in the blood of patients with B-CLL, in some cases accounting for up to 50% of all circulating CD4+ T cells, as well as increased expression of PF by CD8+ cells. Since B-CLL is often accompanied by humoral autoimmunity or immuno-deficiency, expansion of CD4+PF+ cells in blood of B-CLL patients may reflect the immunoregulatory function of these cells. CD4+PF- T cells have also recently been documented in several autoimmune disorders. Regulatory T cells (Tregs) have been identified as an anergic CD4+CD25+CD45RBdim population.

The aim of this study was to determine whether the ex vivo expanded CD4+PF+ cells were able to kill autologous B-CLL cells via a PF-mediated pathway. We also investigated whether CD4+PF+ cells expressed a regulatory phenotype.

**Design and Methods**

**Patients**

With the approval of the local Ethical Committee we studied 26 B-CLL patients (3 women and 23 men) attending the outpatients clinics at UCLH Trust. Patients in disease stages Rai 1-4 were studied (Table 1). Twenty-three patients were deemed untreated since they had received no treatment for at least 4 months prior to investigation. Two patients were treated with chlorambucil and one with steroids. The white blood cell (WBC) counts varied from 2.4 to 90.4×10^9/L.

**Cell preparation**

Peripheral blood mononuclear cells (PBMC) were separated from heparinized blood on a Lymphoprep gradient (Gibco), washed twice and resuspended in RPMI-1640 (Gibco) supplemented with 10% fetal calf serum (FCS, Gibco) and streptomycin/penicillin (Gibco). The cell concentration was adjusted to 5×10^6 cells/mL.

**Enrichment of CD4+ and CD8+ cells**

Cells were enriched for CD4+ and CD8+ populations using positive isolation kits (Dynal) according to the manufacturer’s instructions. Beads were coated with anti-CD4 or anti-CD8 mouse IgM monoclonal antibodies (mAbs) and then attached beads were removed using Detachabead (Dynal) according to the manufacturer’s instructions. The purity of the isolated CD4+ or CD8+ cells was evaluated by staining with anti-CD4 or anti-CD8 mAbs, conjugated anti-CD19 and FITC-conjugated anti-CD5 mAbs (Pharmingen) and analyzed by flow cytometry. Only cell suspensions containing > 98% B-CLL cells were used for cytotoxic assays. The proportion of CD19:CD5+ cells in the enriched B-cell population was negligible. The viability of the isolated cells was monitored using trypan blue, and only viable cell suspensions (>95%) were used for the assays.

**Cytotoxicity assay**

Purified target B-CLL cells (10^6 cells/mL) were labeled with the red fluorescent dye PKH26 (Sigma) according to the manufacturer’s instruction. The cells were washed and adjusted to 10^6 cells/mL in RPMI-1640. The CD4+ and CD8+ cell suspensions (effector cells) used to kill the target B cells were adjusted to 2.0×10^6 cells/mL in RPMI-1640 and diluted so that addition of 100 µL of each would give effector/target (E/T) cell ratios of 20:1, 10:1, 5:1 and 1:1 when added to 100 mL of target cells in 96-well round-bottomed microplates (Nunc). Bispecific anti-CD3 x anti-CD19 antibody (OKT3×RFB9) was added at a final concentration of 2 µg/mL. Control wells were without BsAb and contained the highest E/T ratio (20:1) or without effector cells at 1.0×10^6 cells/mL in 200 µL of RPMI-1640 to control for spontaneous apoptosis. Cell mixtures were incubated for 4, 24 or 48 hours at 37°C and the cytotoxicity detected only in the red fluorescent dye marked target B-CLL cells (in FL-2) as described below.

Bispecific antibodies were prepared using a chemical cross-linker to couple mAb Fab’ fragments via their hinge-region SH groups and the optimal concentration of BsAb for cytotoxicity was determined in preliminary studies using allogeneic B-CLL target cells and control CD8+ cells. Apoptosis was measured primarily by the loss of mitochondrial membrane potential as detected by decreased emission from the dye 3,3’dihy-dothyodide (DiO) and used for cytotoxic assays.

**Enrichment of B-CLL cells**

B cells were obtained by negative depletion of peripheral blood T cells and monocytes using anti-CD4, anti-CD8 (Sigma), anti-CD14 and anti-CD3 (Pharmingen) mAbs and Dynal beads according to the manufacturer’s instructions. The enriched B cells were washed twice and used for cytotoxicity assays. The purity of the isolated B-CLL cells was checked by staining with CyC-conjugated anti-CD19 and FITC-conjugated anti-CD5 mAbs, (Pharmingen) and analyzed by flow cytometry. Only cell suspensions containing > 98% B-CLL cells were used for cytotoxic assays. The proportion of CD19:CD5+ cells in the enriched B-cell population was negligible. The viability of the isolated cells was monitored using trypan blue, and only viable cell suspensions (>95%) were used for the assays.

**Table 1. Patient’s data.**

<table>
<thead>
<tr>
<th>Stage (Rai)</th>
<th>Number of patients</th>
<th>WBC×10^9/L</th>
<th>Mean ± SD*</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 None</td>
<td></td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>1</td>
<td>7</td>
<td>7.1-20.7</td>
<td>12.8±5.0</td>
</tr>
<tr>
<td>2</td>
<td>9 (1 - Chlorambucil)</td>
<td>19.2-90.4</td>
<td>46.0±28.1</td>
</tr>
<tr>
<td>3</td>
<td>6 (1 - Chlorambucil)</td>
<td>9.1-61.5</td>
<td>28.0±19.1</td>
</tr>
<tr>
<td>4</td>
<td>4 (1 - Steroids)</td>
<td>2.4-10</td>
<td>5.4±2.7</td>
</tr>
</tbody>
</table>

*The patients were untreated unless otherwise stated. *Standard deviation.
dihexyloxycarbocyanine iodide (DiOC₆, Sigma), a generally accepted method for the evaluation of effector cell induced apoptosis. DiOC₆ was added at a final concentration of 40 nM, 15’ prior to the end of the incubation period and the green fluorescence of the dye measured by flow cytometry by gating on the red-linker marked target B-CLL cells. The results were expressed as percentages of apoptotic cells (dull green fluorescence) over the total including viable cells (bright green fluorescence) minus spontaneous apoptosis seen in the same gated population, unless indicated otherwise. To confirm our apoptosis results obtained with DiOC₆, in some experiments apoptosis was measured by cell binding of annexin V. Briefly, the labeled B-CLL cells from 8 patients following incubation with CD4+ T cells were washed twice with Ca²⁺-free binding buffer and stained with annexin V-FITC (APO-1 kit, Sigma) for 10 minutes at room temperature. Green fluorescence staining of PKH26-labeled cells was measured and the results expressed as percentages of apoptotic annexin V binding cells.

Mechanism of induction of apoptosis by CD4+ T cells

To determine whether the apoptosis of target cells involved PF and/or Fas-mediated pathways, CD4+ or CD8+ cells (0.2x10⁶ in 200 µL of RPMI-1640) were pretreated for 2 hr at 37°C with either 100 nM of concanamycin A (CMA, Sigma), which causes the degradation of PF-containing granules or 10 µM of brefeldin A (BFA, Sigma) which disrupts Fas/FasL-mediated interactions. The cells were then washed three times and co-cultured with target cells at the highest E/T cell ratio (20:1) for 48h in the presence of BsAb. To study the possible bystander killing through TNFα, anti-TNFα mAb (Upstate, clone 2C8) was added at a final concentration of 500 ng/mL (as recommended by the manufacturer), at the beginning of the culture together with BsAb at a 20:1 E/T cell ratio for 48h.

Expression of perforin by T cells with a regulatory phenotype

Peripheral blood mononuclear cells were prepared as described above and stained with optimal concentrations of CyC-conjugated anti-CD4 and PE-conjugated anti-CD25 mAbs or CyC-conjugated anti-CD4 and PE-conjugated anti-CD45RB mAbs (Pharmingen) previously titrated to give optimum conditions. They were then fixed, permeabilized and treated with FITC-anti-PF mAb (Ancell) as described previously. In additional experiments PBMC from 12 B-CLL patients and 8 controls were stained with anti-CD4, anti-PF and PE-anti-IL-10 mAbs (Pharmingen). The cells were analyzed by flow cytometry and the results expressed as the mean fluorescence intensity (MFI) of CD45RB in PF+ and PF−CD4+ T cells and percentages of CD4+PF−CD25+ cells or CD4+PF+IL10− cells.

Statistical analysis

The data were analyzed using Student’s t-test, correlation coefficient and Mann-Whitney non-parametric test where appropriate. Data shown in the figures represent means ± standard deviations.

Results

Both CD4+ and CD8+ cells induce apoptosis of autologous B-CLL cells

Both CD4+ and CD8+ cells isolated from the blood of B-CLL patients induced apoptosis of autologous leukemic cells in the presence of anti-CD3 × anti-CD19 BsAb at an E/T ratio in the range of 20:1 – 5:1 (Figure 1). The results show that CD4+ T cells induce apoptosis of autologous B-CLL cells. CD8+ T cells, as expected, also induce apoptosis. The level of apoptosis was different for each patient’s tumor cells and varied between 6.6 and 68.0% of DiOC₆dim B-CLL cells (17 patients) and CD8+ cells (19 patients) with spontaneous levels of apoptosis of the B-CLL cells subtracted. Data from two patients treated with chlorambucil and one treated with steroids are shown by open circles and triangles. A correlation coefficient was used to compare the levels of cytotoxicity mediated by CD4+ and CD8+ cells from individual patients.
22 patients) and 6.4 - 57.8% for CD8+ cells (19 out of 21 patients). Only negligible amounts of cytotoxicity (<5%) were seen in the majority of the cases without BsAb. There was no correlation between the level of cytotoxicity induced by CD4+ or CD8+ T cells and stage of the disease (data not shown). However, there was a significant negative correlation (p=0.004) between the white blood cell (WBC) count and cytotoxic activity of CD4+ (but not CD8+ cells), the effector cells from the patients with a WBC of more than 25×10^9 showing decreased cytotoxic activity (Figure 2, pooled data). The level of apoptosis induced by the CD4+ cells was directly related to the percentages of cells containing perforin (correlation coefficient of 0.75): 19.8±11.9% of CD4+ PF+ cells and 49.9±20.7% of CD8+PF+ cells.

CD4+ mediated cytotoxicity is time-dependent

Apoptosis of autologous B-CLL cells induced by both CD4+ and CD8+ cells increased with time in culture (Figure 3). Data are shown for patients from whom sufficient CD4+ T cells (4 patients, Figure 3A) and CD8+ T cells (5 patients, Figure 3B) could be obtained for a complete time course at an E/T ratio of 20:1 or 10:1. Spontaneous apoptosis of the B-CLL cells alone is also shown. A time-related increase in apoptosis appeared to be a characteristic of CD4+ cells whereas that induced by CD8+ cells had generally plateaued by 24 hours. We did not study cytotoxicity beyond 48h, since B-CLL cells from the majority of the patients had been killed by this time point. To confirm these data we studied annexin V binding by B-CLL target cells in eight patients who had shown increased apoptosis as measured by the DiOC6 assay. The results for three representative patients show similar profiles for a time-related induction of CD4+-induced apoptosis measured by annexin-V-FITC binding to the cell surface of apoptotic B-CLL cells (Figure 3C).

Apoptosis of autologous B-CLL cells induced by CD4+ and CD8+ cells was dependent on effecter cell number

A representative experiment shows the effect of increasing the E/T ratio on apoptosis of B-CLL cells measured by DiOC6 staining after 24 and 48 hours in culture (Figure 4). Data from three individual patients show the level of CD4+ T-cell-induced apoptosis of B-CLL cells decreased with a decreasing E/T ratio with some minimal cytotoxicity detectable at an E/T ratio of 1:1; Figure 5A). Pooled data from patients tested at different E/T ratios show the same trends in dependence of cytotoxicity on E/T ratios (Figure 5B). Interestingly, at 10:1 and 20:1 E/T ratios CD8+ cells were approaching plateau levels for cytotoxicity as shown for individual patients (n=3: Figure 5C) and pooled patient data (Figure 5D).
CD4+ T cells kill autologous B-CLL cells via a perforin-mediated pathway

CD8+ T cells have been shown to induce apoptosis primarily through a PF-mediated pathway.\textsuperscript{14,15} In order to determine whether the apoptosis of B-CLL cells induced by \textit{ex vivo} CD4+ cells from B-CLL patients was also mediated through a PF-dependent mechanism, effector cells were treated with CMA prior to addition of target leukemic cells. Cytotoxicity mediated by CD4+ cells from the majority of patients (8 out of 11) was blocked by concanamycin (Figure 6A: $p \leq 0.025$). In only three patients, did concanamycin fail to completely block the cytotoxic effect of CD4+ cells. As expected, the cytotoxicity mediated by CD8+ cells at 48 hours was completely blocked by this drug (Figure 6B, $p \leq 0.029$).

To investigate the role of the Fas/FasL pathway in induction of apoptosis by CD4+ cells, the cells were precultured with brefeldin. In addition, to test whether TNF\textit{\alpha} had a role in cytotoxicity we included anti-TNF\textit{\alpha} antibodies in some cultures. Neither of these treatments interfered with cytotoxicity mediated by either CD4+ or CD8+ T cells. (Figures 6A and 6B).

CD4+PF+ cells do not belong to the terminally differentiated T reg population, but are enriched with CD25+ and IL10+ cells compared with CD4+PF\textsuperscript{-} cells

We found that PF+ CD4+ cells were enriched in CD45RB\textsuperscript{bright} cells as measured by the mean fluorescence intensity (MFI) of CD45RB, whilst the PF+ CD4+ cells contained significantly more CD45RB\textsuperscript{dim} cells (Figure 7A, $p=0.005$). This suggests that the proportion of terminally differentiated Treg cells within the PF+ CD4+ cell population is lower than in PF- CD4+ cells.

Figure 4. Representative profiles showing an increase in apoptosis with E/T cell ratio for both CD4+ and CD8+ effector cells. B-CLL target cells were cultured with CD4+ or CD8+ cells at E/T cell ratios of 20:1, 10:1, 5:1 and 1:1 in the presence of BsAb for 48 hr. Apoptosis was measured as described in Figure 1. The values shown have spontaneous apoptosis subtracted. Only the statistical differences with $p$ values <0.05 are indicated.

Figure 5. Dose-dependence of effector cells on the cytotoxic activity of CD4+ and CD8+ cells. B-CLL target cells were cultured with CD4+ or CD8+ cells at E/T cell ratios 20:1, 10:1, 5:1 and 1:1 in the presence of BsAb for 48hr. Apoptosis was measured as described in Figure 1. Data are shown for individual patients (n=3) for CD4+ effector cells (SA) and pooled data for CD4+ cells (SB): $p$ values show the differences with the highest 20:1 E/T ratio. Individual patient data (n=3) for CD8+ effector cells (SC) and pooled data for CD8+ cells (SD) are also shown: the $p$ value shows the difference between 1:1 and all other E/T ratios used.
population in B-CLL patients is low, as defined by expression of CD45RB. However, significantly more PF-CD4+ cells from B-CLL patients expressed CD25 (p=0.011) than did their control counterparts, whilst the proportion of CD25+ cells in the PF-CD4+ population was similar in both controls and B-CLL patients (Figure 7B). In addition, more CD4+ PF+ cells in patients with B-CLL constitutively expressed IL-10 (Figure 7C), than did the PF- population (8.4 ± 9.6 versus 1.5 ± 2.3, p=0.009). This value was significantly higher than that of the CD4+ PF+ cells in healthy controls (2.1±0.9, p=0.015) suggesting that in B-CLL patients the CD4+ PF+ population is enriched with immunoregulatory T cells as determined by constitutive expression of IL10.

**Discussion**

Although a property previously attributed to CD8+ T cells, in this study we show that CD4+ T lymphocytes were able to kill autologous B-CLL cells through a bispecific antibody directed to CD3 and CD19.10 We have recently found a significant expansion of CD4+ T cells with the cytotoxicity-associated phenotype, expressing perforin and granzymes in patients with B-CLL.16 In this study we specifically investigated whether ex vivo CD4+ T cells induce apoptosis of autologous B-CLL cells through the cytotoxicity-associated machinery that they contain. In addition we studied whether these cells belonged to the T regulatory population with CD4+CD25+CD45RBdim phenotype.

The major finding reported here is that ex vivo CD4+ cells, like CD8+ cells, were able to induce significant apoptosis of autologous B-CLL cells in the presence of anti-CD19×CD3 BsAb (Figure 1). There was some correlation between the ability of both CD4+ and CD8+ cells in individual patients to induce cytotoxicity (0.790), although the individual values for apoptosis of B-CLL cells varied from 6.6% to 68.0% for CD4+ cells and from 6.4% to 57.8% for CD8+ cells. In our study, CD4+ cells, like CD8+ cells, induced apoptosis of the target cells in a dose-dependent manner (Figures 4 and 5), a characteristic feature of classical cytotoxic cells.11 Since we pre-labeled the target B-CLL cells with a red membrane linker we were able to specifically detect apoptosis in this population and ignore any apoptosis of non-CLL B cells. Previous studies by others have also shown killing of malignant B-CLL cells through BsAb to CD3 and CD19 together with anti-CD28 in a 4 hr cytotoxicity assay.10 However, in their studies, blood lymphocytes were activated for 9 days prior to addition of B-CLL target cells and the pathway utilized was believed to be Fas/FasL. In our experiments we anticipated that since the patient’s CD4+ T cells (and CD8+ T cells) had the CD28−CD57+ phenotype of mature cytotoxic cells,16 they would directly kill the autologous tumour cells in the presence of BsAb linking them to the target cells upon activation via CD3.

Although there was some limited cytotoxicity by the CD4+ (and more so by the CD8+ T cells) measured at 4 hours, in the majority of cases the cytotoxicity by CD4+ cells was higher at 24 and 48 hours (Figures 3A and 3B). After more prolonged exposure to the effector cells the majority of B-CLL cells had reached the later stages of apoptosis (ie. cell shrinkage, data not shown) indicating irreversibility of the process. Induction of target B-CLL apoptosis was confirmed by the binding of annexin V (Figure 3C). Thus, unlike assays using pre-generated cytotoxic T cells11 or NK cells, there was a time requirement to obtain optimum killing. This could account for the lack of evidence in previous studies of ex vivo CD4+ mediated cytotoxicity measured in classical 4h cytotoxicity assays.25

The reason for the delay in cytotoxicity is unclear. One possibility is that CD4+ cells need to be activated to induce apoptosis. However, both CD4+ and CD8+ cells from two patients with high levels of perforin expression induced up to 41.8% of apoptosis of target Ramos
and DG75 B cells after only 4h in the presence of BsAb (data not shown). It therefore seems likely the CD4+ T cells are mature cytotoxic cells ex vivo. In further support of the concept that the CD4+ T cells are mature cytotoxic cells ex vivo, CD4+ PF+ cells from control and virus-infected individuals showed killing of EBV-infected target cells mediated through Staphylococcal enterotoxin B within 4 hours, demonstrating that these cells are capable of releasing perforin and killing immediately.26

Another possibility is that the target B-CLL cells themselves are not susceptible ex vivo to the action of perforin and granzymes but acquire this susceptibility during culture. In fact, a previous study by others indicated that cytotoxicity mediated by T cells is enhanced by pre-activation of the target B-CLL cells by phorbol ester.27 Consistent with the necessity for the target B cells to be activated, we found that some molecules were up-regulated on B-CLL cells in culture with the effector CD4+ T cells. Expression of CD86 was increased on B-CLL cells (in 5 patients) from 4.9±3.0% when cultured alone for 48 hrs to 13.7±4.4% in the presence of autologous CD4+ T cells and BsAb (p=0.0039). B-CLL cells cultured with autologous CD8+ cells and BsAb also up-regulated CD86, although to a lesser extent (8.8±6.6%, p=0.082). Another possibility is that the effector T cells might recognize leukemic cells dying in culture and aid in their demise. Previous data from a variety of sources have indicated that CD8+ T cells primarily induce cytotoxicity through perforin-mediated mechanisms14,15 and have suggested that the main mechanism by which CD4+ T cells induce apoptosis is through the Fas/FasL pathway.14,28 Since the frequency of CD4+ T cells in B-CLL patients containing perforin is significantly higher than in normal controls16 it was important to determine whether CD4+ T-cell cytotoxicity was mediated through this molecule. Concanamycin A has been shown to disrupt the granules in cytotoxic T cells and to inhibit PF-mediated cytotoxicity.23,29 Our data show that, like CD8+ T-cell-mediated cytotoxicity, CD4+ T-mediated killing is blocked by concanamycin A in the majority of cases (Figure 6).

Since for three patients studied, blocking of apoptosis induced by CD4+ T cells was not completely inhibited by concanamycin A, we tested whether other PF-independent mechanisms could also be operating. Brefeldin A, a Fas/FasL blocker24 failed to alter the cytotoxicity of either CD4+ or CD8+ T cells (Figure 6). This was not surprising since cross-linking of Fas expressed by B-CLL cells is not effective in inducing apoptosis30 (and unpublished observations). Although unlikely to be playing a role in our experimental system, it has recently been shown that B-CLL cells become susceptible to Fas-induced apoptosis after 4–5 days of activation via CD40 suggesting that this mechanism could be operating in longer term cultures,31 as compared to a faster PF-mediated killing. TNFα has been shown to be produced by cytotoxic T cells,32 but in our experiments anti-TNFα also failed to block cytotoxicity. This is not surprising since TNFα has been shown to induce proliferation of B-CLL cells and even protect against in vitro apoptosis.33 Another member of the TNFα family, TRAIL, which has been shown to be produced by cytotoxic T cells34 failed to induce apoptosis when added in vitro to B-CLL cells.
CD4+ PF+ T cells are capable of killing autologous B-CLL or PF+ through a perforin-mediated mechanism. This could also suggest that they were regulatory and specific for tumour-associated antigens and could potentially play a role in killing B-CLL cells in vivo. That cytotoxic precursors do exist in vivo is suggested by the fact that autologous T lymphocytes recognize B-CLL tumor-associated antigens such as IgVH CDR3 region and that cytotoxic T cells have been generated, in vitro, against tumor-associated antigens from B-CLL. Our data suggest the potential role of CD4 (and CD8) mediated cytotoxicity directed towards autologous leukemic cells as a future component of anti-tumor and anti-viral therapy.

Since CD4+ cells that are CD25+ and CD45RBdim have recently been shown to be terminally differentiated T regulatory cells, we determined whether the PF+ CD4+ population contained cells with immunoregulatory phenotype. Our finding that the intensity of CD45RB expression was higher in PF+ population in B-CLL patients than from the controls suggested that there is a high frequency of CD4+ CMV-specific T cells in patients with B-CLL (P. Moss, personal communication). Experiments are currently underway to test this possibility. Alternatively, they might also have some specificity for tumour-associated antigens and could potentially play a role in killing B-CLL cells in vivo. That cytotoxic precursors do exist in vivo is suggested by the fact that autologous T lymphocytes recognize B-CLL tumor-associated antigens such as IgVH CDR3 region and that cytotoxic T cells have been generated, in vitro, against tumor-associated antigens from B-CLL. Our data suggest the potential role of CD4 (and CD8) mediated cytotoxicity directed towards autologous leukemic cells as a future component of anti-tumor and anti-viral therapy.

In conclusion, we have provided evidence that the ex vivo CD4+ PF+ T cells are capable of killing autologous B-CLL tumor cells in vitro through a perforin-mediated mechanism. In addition, more of these cells in B-CLL contain IL-10 and express CD25 suggesting that they might have a regulatory role in B-CLL. Further experiments are in progress to determine the exact nature of these cells in relation to their origin, differentiation state, function and specificity in B-CLL patients.

NP helped to design the experiments, carry out and interpreted results, produced the first draft of the paper and approved version to be published. LK carried out experiments and analyzed data. KP helped in drafting article and gave final approval for it to be published. AJ helped to design the experiments, helped with revising the first draft, approved final version to be published. KY clinician providing patients, helped with interpretation and revising manuscript, approved final version. MG provided bispecific antibodies, helped in design of experiments, revised article and approved final version. AA helped in the design and interpretation of experiments related to Tregs, revised the paper, approved the final version. PM was involved in original concept and design, interpretation etc. Involved in first and subsequent drafts, approved final version and submitted it. The authors would like to acknowledge the help of Dr M Vukmanovic-Stjetic in the study on T regulatory cells and Ms AL Tutt for supplying bispecific anti-CD3 × anti-CD19 mAb, Isobel Howard for secretarial help with patients’ records and Dr T. Kipps for helpful discussion. The authors reported no potential conflicts of interest.

This work was supported in part by a grant from the Special Trustees of the Middlesex Hospital and UCH and Royal Free & UCL Medical School and INTAS EU Grant 2239.


References

Cytotoxic CD4+ T cells in B-CLL


